Tongue Cancer Clinical Trial
Official title:
A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining erlotinib with docetaxel may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells. Phase I trial to study the maximum tolerated dose (MTD) of combining erlotinib with docetaxel and radiation therapy in treating patients who have locally advanced head and neck cancer
PRIMARY OBJECTIVES:
I. Determine MTD and toxicity of combination of EGFR inhibitor (OSI-774), docetaxel, and
radiation.
II. Pharmacokinetic profile of OSI-774 alone and in combination with docetaxel.
SECONDARY OBJECTIVES:
I. Determine the overall and complete response rate of this combination.
II. Determine overall, disease free, and progression free survival of this combination.
- EGFR expression and phosphorylation status
- Serum markers of angiogenic activity VEGF, sVEGFR-2, sKIT, ICAM, PDGF
- Fluorescence in situ hybridization (FISH) for EGFR, ERBB2, PDGFR-β for gene
amplification
- DNA-sequencing of EGFR and ERBB2 genes from DNA extracted from pretreatment biopsy
material for mutation screening
- Gene expression profiling on pre-treatment biopsy material to identify predictors of
response to treatment
- Apoptosis (TUNEL assay)
- Ki67 (nuclear proliferation antigen).
OUTLINE: This is a dose-escalation study of erlotinib and docetaxel.
Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral
erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9.
Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue
erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity.
Patients who had N2 or greater cervical lymph node involvement at baseline or have residual
neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion
of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing
is complete.
Cohorts of 3-6 patients receive escalating doses of erlotinib and docetaxel until the MTD is
determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients
experience dose-limiting toxicity.
Patients are followed every 16 weeks for 1 year after completion of erlotinib, every 24
weeks for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01469429 -
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04041141 -
Oral Stent Device for Radiation Treatments of Oral Cancers
|
||
| Completed |
NCT00407810 -
Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00096512 -
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT01637194 -
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT00033618 -
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
|
Phase 2 | |
| Completed |
NCT01816841 -
Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care
|
N/A | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Completed |
NCT04059861 -
Ultrasound in Tongue Cancer- a Help to Decide Depth of Invasion and to Improve the Surgical Margin
|
N/A | |
| Recruiting |
NCT01854021 -
Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer
|
N/A | |
| Withdrawn |
NCT01674374 -
Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy
|
Phase 2 | |
| Completed |
NCT01816984 -
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01528137 -
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT04337853 -
Radiotherapy of Tongue Cancer Using an Intraoral Stent
|
Phase 1 | |
| Completed |
NCT01806675 -
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01847326 -
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
|
Phase 1 | |
| Terminated |
NCT02177838 -
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
|
N/A | |
| Completed |
NCT00114283 -
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT04126226 -
Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy
|
N/A | |
| Completed |
NCT00293462 -
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 3 |